Furagin tablets 0.05g, No. 30 Obolenskoe

Infectious and inflammatory diseases: cystitis, urethritis, pyelonephritis; infections of the female genital organs; prevention of infections during urological operations, cystoscopy, catheterization.

For therapeutic purposes, adults are prescribed on the first day of therapy, 100 mg (2 tablets) 4 times a day on subsequent days - 100 mg 3 times a day after meals for 7-14 days.

For children, the drug is prescribed in a daily dose of 5-7 mg / kg of body weight with long-term treatment - in a daily dose of 1-2 mg / kg. The course of treatment is 7-8 days.

If necessary, after 10-15 days, the course of treatment can be repeated.

For prophylactic purposes, the drug is prescribed 50 mg (1 tablet) once a day (preferably in the evening).

Active ingredient: furazidine 50 mg.

Excipients: lactose (milk sugar), microcrystalline cellulose, potato starch, crospovidone (Kollidon CL-M), povidone (low molecular weight medical polyvinylpyrrolidone), croscarmellose sodium (primellose), calcium stearate, polysorbate. (Tween-80).

• pregnancy;

• lactation;

• hypersensitivity to nitrofuran derivatives;

• impaired renal function;

• impaired liver function;

• children under 3 years of age (for this dosage form)

Carefully:

• deficiency of glucose-6-phosphate dehydrogenase;

• diseases of the nervous system.

Trade name of the drug

Furagin

International non-proprietary name

Furazidine

Dosage form

pills

Composition

Active ingredient: furazidine 50 mg.

Excipients: lactose (milk sugar), microcrystalline cellulose, potato starch, crospovidone (Kollidon CL-M), povidone (low molecular weight medical polyvinylpyrrolidone), croscarmellose sodium (primellose), calcium stearate, polysorbate. (Tween-80).

Description

Tablets from yellow to yellow with an orange tinge, flat-cylindrical with a bevel.

Pharmacotherapeutic group

antimicrobial agent, nitrofuran

ATX code

D08AF

Pharmacodynamics:

Antimicrobial agent derived from nitrofuran.

Effective against gram-positive cocci (Staphylococcus spp. Streptococcus spp.), Gram-negative rods (E. coli Salmonella spp. Shigella spp. Klebsiella spp.). Resistant Plasmodium aeruginosa Enterococcus spp. Acinetobacter spp. most strains of Proteus spp. Serratia spp.

The mechanism of action is associated with inhibition of nucleic acid synthesis. Depending on the concentration, it has a bactericidal or bacteriostatic effect.

Against most bacteria, the bacteriostatic concentration ranges from 10-20 ?g / ml. The bactericidal concentration is approximately 2 times higher. Under the influence of nitrofurans in microorganisms, the activity of the respiratory chain and the tricarboxylic acid cycle (Krebs cycle) is suppressed, as well as other biochemical processes are suppressed, which leads to the destruction of their membrane or cytoplasmic membrane. As a result of the action of nitrofurans, microorganisms secrete less toxins, and therefore an improvement in the general condition of the patient is possible even before the pronounced suppression of the growth of microflora. Nitrofurans, unlike many other antimicrobial drugs, not only do not suppress the body's immune system, but, on the contrary, activate it (increase the complement titer and the ability of leukocytes to phagocytose microorganisms).

Pharmacokinetics:

Absorption - in the small intestine by passive diffusion.

It is metabolized in the liver.

Excreted by the kidneys 6%, the average concentration of furazidine in urine exceeds its bacteriostatic concentration.

Indications:

Infectious and inflammatory diseases: cystitis, urethritis, pyelonephritis; infections of the female genital organs; prevention of infections during urological operations, cystoscopy, catheterization.

Contraindications:

• pregnancy;

• lactation;

• hypersensitivity to nitrofuran derivatives;

• impaired renal function;

• impaired liver function;

• children under 3 years of age (for this dosage form)

Carefully:

• deficiency of glucose-6-phosphate dehydrogenase;

• diseases of the nervous system.

Method of administration and dosage:

For therapeutic purposes, adults are prescribed on the first day of therapy, 100 mg (2 tablets) 4 times a day on subsequent days - 100 mg 3 times a day after meals for 7-14 days.

For children, the drug is prescribed in a daily dose of 5-7 mg / kg of body weight with long-term treatment - in a daily dose of 1-2 mg / kg. The course of treatment is 7-8 days.

If necessary, after 10-15 days, the course of treatment can be repeated.

For prophylactic purposes, the drug is prescribed 50 mg (1 tablet) once a day (preferably in the evening).

Side effects:

Possible: dyspeptic manifestations - nausea, vomiting, decreased appetite.

From the side of the central nervous system: dizziness; headache; development of polyneuritis.

Liver dysfunction.

Allergic reactions: urticaria; pruritus including papular.

Overdose:

Symptoms: neurotoxic reactions, polyneuritis, abnormal liver function, acute toxic hepatitis.

Treatment: cancellation of Furagin; intake of large amounts of liquid; symptomatic therapy; antihistamines; B vitamins.

There is no specific antidote.

Interaction:

There is no data

Special instructions:

To prevent side effects, drink plenty of fluids and antihistamines.

To prevent the development of neuritis, it is necessary to prescribe B vitamins.

Release form / dosage:

Tablets 50 mg.

Packaging:

On 10 15 20 or 30 tablets in a blister strip packaging from a film of polyvinyl chloride and printed aluminum foil varnished.

1 or 3 blisters with instructions for use in a cardboard box.

Storage conditions:

List B. In a dry, dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life:

5 years. Do not use after the expiration date indicated on the package.

Vacation conditions

On prescription

Manufacturer

Joint-stock company 'Pharmaceutical enterprise' Obolenskoye '(JSC' FP 'Obolenskoye'), 142279, Moscow region, Serpukhovsky district, g. Obolensk, rp. Obolensk, district of the industrial area Obolensk industrial zone, vld. No. 39, building 1, Russia

Marketing Authorization Holder / Organization Receiving Consumer Claims:

JSC 'FP' Obolenskoye '